Aims & Scope

The Journal of Hematology and Oncology Research publishes high-quality, rigorously reviewed research spanning the full spectrum of hematology and oncology. We welcome work that advances understanding of benign and malignant blood disorders, solid tumors, and related conditions across basic, translational, clinical, and population-level research.

The journal considers original research articles, systematic reviews and meta-analyses, clinical case reports, methods and protocols, short communications, review articles, translational research, and clinical trial reports that address hematology and oncology in adults and children. We are interested in studies ranging from molecular and cellular mechanisms, genomics, and immunology to diagnostics, therapeutics, supportive care, survivorship, health services, and implementation in real-world settings.

We particularly encourage submissions on topics such as hematologic malignancies and solid tumors; benign hematologic conditions (including anemia, coagulation and platelet disorders, hemoglobinopathies, and transfusion medicine); cancer prevention and early detection; diagnostic and prognostic biomarkers; imaging and laboratory diagnostics; systemic therapies, cellular therapies, radiotherapy, and surgical oncology; hematopoietic stem cell transplantation; palliative and supportive care; quality of life and survivorship; health disparities and access to cancer and hematology care; and outcomes and epidemiologic research in diverse global contexts.

The Journal of Hematology and Oncology Research serves a multidisciplinary audience of clinicians, clinical and translational investigators, laboratory scientists, trialists, epidemiologists, and health services researchers. We welcome a broad range of quantitative, qualitative, and mixed-methods approaches, provided that studies are methodologically sound, ethically conducted, and clearly report their implications for hematology and oncology practice, policy, or future research.

Two Convenient Submission Methods

We offer two streamlined pathways for manuscript submission, designed to accommodate your preferences and workflow. Choose the method that works best for your research submission needs.

Article Types We Accept

The Journal of Hematology and Oncology Research publishes diverse research contributions that advance our understanding of blood disorders, hematologic malignancies, and cancer biology. We welcome submissions across the full spectrum of hematology and oncology research, including basic, translational, clinical, epidemiologic, and health services studies in both benign and malignant conditions.

Pre-Submission Checklist

Before submitting your manuscript, ensure you have completed all necessary preparations. This checklist helps guarantee a smooth submission process and faster editorial review.

Reporting Guidelines

The Journal of Hematology and Oncology Research requires adherence to internationally recognized reporting standards to ensure transparency, reproducibility, and methodological rigor across all published research.

CONSORT Reporting for Clinical Trials
All Clinical Trial Reports submitted to the Journal of Hematology and Oncology Research must adhere to the CONSORT (Consolidated Standards of Reporting Trials) guidelines. Authors should structure their manuscripts to address all relevant CONSORT checklist items, including trial design, participant flow, interventions, outcomes, sample size, randomization, blinding, statistical methods, and harms.

Authors are required to upload a completed CONSORT checklist and a participant flow diagram as supplementary files at the time of submission. The checklist should indicate page numbers where each item is addressed in the manuscript. Trials that do not comply with CONSORT may be returned to authors for revision prior to peer review or rejected on reporting quality grounds.

PRISMA Reporting for Systematic Reviews and Meta-Analyses
Systematic Reviews and Meta-Analyses submitted to the Journal of Hematology and Oncology Research must follow the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Authors should clearly describe search strategies, eligibility criteria, study selection, data extraction, risk of bias assessment, and synthesis methods in accordance with PRISMA.

Authors are required to submit a completed PRISMA checklist and a PRISMA flow diagram as supplementary materials. The checklist must specify the page numbers where each item is addressed. Manuscripts that do not meet PRISMA reporting standards may be returned for revision before peer review or declined due to inadequate reporting.

STROBE Reporting for Observational Studies
Observational studies (including cohort, case-control, and cross-sectional designs) in hematology and oncology should comply with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. This applies to clinical, translational, and population-based observational research.

Authors are expected to structure their manuscripts to address key STROBE items related to study design, setting, participants, variables, data sources, bias, study size, statistical methods, and limitations. A completed STROBE checklist, indicating page numbers for each item, should be uploaded as a supplementary file at submission. Submissions that do not meet basic STROBE reporting expectations may be returned to authors for improvement prior to peer review.

STARD Reporting for Diagnostic Accuracy and Biomarker Studies
Diagnostic accuracy studies and biomarker evaluations in hematology and oncology should follow the STARD (Standards for Reporting Diagnostic Accuracy Studies) guidelines. This includes studies assessing the performance of laboratory tests, imaging modalities, or biomarker panels.

Authors should report key elements such as participant selection, index tests and reference standards, test methods, statistical measures of accuracy, and handling of indeterminate and missing results in line with STARD. A completed STARD checklist, with page references for each item, must be submitted as a supplementary file. Manuscripts that do not adequately report diagnostic accuracy methods and results may be returned for revision before peer review.

SPIRIT Guidance for Trial Protocols
Protocols for interventional clinical trials in hematology and oncology submitted under Methods & Protocols or related article types should follow the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. SPIRIT provides a minimum set of items that should be addressed in trial protocols to ensure clarity, transparency, and reproducibility.

Authors should ensure that key SPIRIT items (including background and rationale, objectives, trial design, eligibility criteria, interventions, outcomes, sample size, allocation, blinding, data collection, statistical methods, monitoring, and ethics) are clearly described. A completed SPIRIT checklist, indicating where each item is covered in the protocol, must be uploaded as a supplementary file at submission. Protocols that do not meet SPIRIT standards may be returned for revision prior to peer review.

SAGER Guidelines for Sex and Gender Reporting
The Journal of Hematology and Oncology Research expects authors to follow the SAGER (Sex and Gender Equity in Research) guidelines when designing, analyzing, and reporting studies in which sex or gender may influence hematologic or oncologic outcomes. This applies to basic, translational, clinical, and population-based research.

Authors should clearly state whether sex and/or gender were considered in the study design, describe the sex/gender distribution of samples or participants, and report sex- or gender-disaggregated analyses where appropriate. If sex or gender were not considered, a brief justification should be provided. Manuscripts that ignore obvious sex or gender considerations without explanation may be returned for clarification or revision.

ARRIVE Guidelines for Animal Research
All animal studies submitted to the Journal of Hematology and Oncology Research must comply with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Authors should provide sufficient detail on animal models, housing and husbandry, experimental procedures, randomization, blinding, sample size, and statistical methods to allow replication and critical appraisal.

Authors are encouraged to submit a completed ARRIVE checklist as a supplementary file, indicating where each item is addressed in the manuscript. Submissions that do not meet basic ARRIVE reporting standards may be returned for revision or declined on methodological grounds.

Data and Code Availability
The Journal of Hematology and Oncology Research requires all empirical research articles to include a Data Availability Statement describing how readers can access the data underlying the findings. Where possible, authors should deposit de-identified datasets and, when applicable, analysis code in appropriate, recognized repositories and provide persistent identifiers (e.g., DOIs or accession numbers).

If data or code cannot be shared due to ethical, legal, or contractual restrictions, authors must clearly explain these limitations in the Data Availability Statement. Manuscripts without a satisfactory Data Availability Statement may be returned to authors prior to peer review.

Clinical Trial Registration
All interventional clinical trials in hematology and oncology submitted to the Journal of Hematology and Oncology Research must be prospectively registered in a publicly accessible trial registry (e.g., ClinicalTrials.gov, ISRCTN, EU Clinical Trials Register, or another WHO-recognized registry) before enrollment of the first participant.

Manuscripts reporting clinical trials must include the trial registration number and registry name in the abstract and Methods section. Trials that were not prospectively registered must provide a clear explanation, and may be considered only at the editor's discretion. Submissions lacking appropriate trial registration information may be rejected without external peer review.

Image Integrity
The Journal of Hematology and Oncology Research requires that all images (including gels, blots, microscopy, and radiologic images) accurately represent the original data. Authors must not manipulate images in a way that could mislead readers, including inappropriate contrast enhancement, selective cropping that omits relevant data, or splicing of images without clear demarcation and explanation.

Basic adjustments (e.g., brightness, contrast, or color balance) are permitted only if applied uniformly to the entire image and if they do not obscure, eliminate, or misrepresent any information. Authors may be asked to provide original, unprocessed image files during peer review or post-publication. Failure to provide original data or evidence of inappropriate manipulation may result in rejection, correction, or retraction.

Statistical Methods and Review
All submissions to the Journal of Hematology and Oncology Research that include quantitative analyses must describe statistical methods in sufficient detail to allow replication and critical appraisal. This includes specifying primary and secondary endpoints, sample size justification, handling of missing data, model assumptions, and any adjustments for multiple comparisons.

Manuscripts may be evaluated by reviewers with statistical expertise when appropriate. Authors should ensure that analyses are planned and conducted in consultation with a qualified statistician or methodologist for complex designs. Submissions with inadequate or inappropriate statistical methods may be returned for revision or rejected on methodological grounds.

Peer Review Timeline

We are committed to providing efficient, rigorous peer review while maintaining the highest standards of scientific integrity. Our transparent timeline helps you plan your publication strategy.

Why Researchers Choose JHOR

The Journal of Hematology and Oncology Research provides a trusted platform for disseminating high-quality research in blood disorders and cancer biology. Our commitment to scientific rigor, transparency, and author support sets us apart.

Submission Guidelines Summary

Following these guidelines ensures efficient processing of your manuscript and helps avoid delays in the review process.

Manuscript Format

Submit manuscripts in Microsoft Word (.doc, .docx) or LaTeX format. PDF submissions are accepted for initial review but final versions must be in editable format. Use standard fonts (Times New Roman, Arial, or Calibri) with 12-point font size, double-spacing, and 1-inch margins on all sides.

Structure Requirements

Original research articles should follow the standard IMRAD structure: Introduction, Methods, Results, and Discussion. Include a structured abstract (Background, Methods, Results, Conclusions) of 250-300 words. Provide 4-6 keywords using MeSH terms or relevant hematology/oncology terminology.

Figure and Table Guidelines

Submit figures as separate files in TIFF or EPS format with minimum 300 DPI resolution. Color figures are encouraged for online publication. Tables should be editable (not images) and include clear headers and legends. Number all figures and tables consecutively and cite them in the text.

Reference Style

Use Vancouver or AMA citation style with numbered references in order of appearance. Include all authors for references with up to 6 authors; for 7 or more authors, list the first 3 followed by "et al." Verify all references are accurate and complete.

Ethical Requirements

Human subject research requires IRB approval and informed consent documentation. Animal studies must comply with ARRIVE guidelines and include IACUC approval. Clinical trials must be registered in recognized databases (ClinicalTrials.gov, ISRCTN, etc.). Declare all competing interests and funding sources.

Data Availability

Include a data availability statement describing where readers can access the data supporting your findings. We encourage deposition of datasets in recognized repositories (e.g., GenBank, GEO, ProteomeXchange, clinical or epidemiologic data repositories) and sharing of research materials and analysis code when possible.

Article Processing Charges (APC)

The Journal of Hematology and Oncology Research charges an Article Processing Charge (APC) to cover the costs of peer review administration, professional production of articles, and indexing services. The APC for this journal is required upon acceptance of your manuscript for publication.

For detailed information about our APC, including current fees and available waivers, please visit our Article Processing Charges page.